Moxifloxacin: An Alternative to Ethambutol for the Treatment of Presumed Ocular Tuberculosis

Ocular Immunology and Inflammation

Volumn 24, Issue 5, 2016, Pages 508-514

  Potter, Jessica ^a   Agrawal, Rupesh ^b,c,d   Barraclough, Claire ^a   Rahman, Farzana ^b   Westcott, Mark ^b   Pavesio, Carlos E ^b,c   White, Veronica ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Anti tubercular therapy (ATT); drug resistant TB; duration of ATT; ethambutol; moxifloxacin; presumed ocular tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; MOXIFLOXACIN; MYCOPHENOLATE MOFETIL; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR INHIBITOR; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERFERON; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; AMPIGINOUS CHOROIDITIS; ARTICLE; CHOROID DISEASE; CHOROIDAL GRANULOMA; CHOROIDITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DRUG EFFICACY; ELECTROCARDIOGRAM; EYE INFLAMMATION; FEMALE; GRANULOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; LIVER TOXICITY; MALE; OCULAR TUBERCULOSIS; OUTCOME ASSESSMENT; RETINA VASCULITIS; SERPIGINOUS CHOROIDITIS; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; ALTERNATIVE MEDICINE; BLOOD; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TUBERCULIN TEST; TUBERCULOSIS, OCULAR; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTITUBERCULAR AGENTS; COMPLEMENTARY THERAPIES; ETHAMBUTOL; FEMALE; FLUOROQUINOLONES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; MALE; MIDDLE AGED; TUBERCULIN TEST; TUBERCULOSIS, OCULAR; YOUNG ADULT;

EID: 84939546437     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2015.1019155     Document Type: Article

References (28)

1. WHO. Global Tuberculosis Report. Geneva, Switzerland:World Health Organisation; 2013. Available from:http://www.who.int/tb/publications/global_report/en/
2. Lou SM, Larkin KL, Winthrop K, et al. Lack of consensus in the diagnosis and treatment for ocular tuberculosis among uveitis specialists. Published Online First:14 July 2014. informahealthcare.com/doi/abs/10.3109/09273948.2014.926936 [last accessed 19 Jul 2014]
3. WHO. Treatment of Tuberculosis:Guidelines, 4th edition. WHO 2009;WHO/HTM/TB/2009.4
4. Caminero JA. Guidelines for clinical and operational management of drug-resistant tuberculosis 2013. Int Union Against Tuberc Lung Dis. 2013
5. National Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice at NICE (UK). Tuberculosis:clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011
6. CDC. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52:1–77. http://www.ncbi.nlm.nih.gov/pubmed/12836625 [last accessed 28 Sep 2014]
7. National Institute for Health and Clinical Excellence. Tuberculosis:clinical diagnosis and management of tuberculosis, and measures for its prevention and control. NICE 2011;NICE Clinical Guideline 117. guidance.nice.org.uk/CG117
8. Tuberculosis in the UK – 2013 report. Public Health England 2013. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139689583
9. PHE. Tuberculosis in the UK 2014 report. 2014
10. London HPA, Bulletin S. London:Tuberculosis for London's health professionals. 2013;1–17
11. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep. 2010;59:1–25. http://www.ncbi.nlm.nih.gov/pubmed/20577159 [last accessed 31 Aug 2014]
12. V.Gupta, A.Gupta, N.A.Rao. Intraocular tuberculosis—an update. Surv Ophthalmol. 52:561–87. doi:10.1016/j.survophthal.2007.08.015
13. V.Dartois. The path of anti-tuberculosis drugs:from blood to lesions to mycobacterial cells. Nature Rev Microbiol. 2014;12:159–67
14. W.L.Hand, R.W.Corwin, T.H.Steinberg, G.D.Grossman. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis. 1984;129:933–7
15. N.Ezer, A.Benedetti, M.Darvish-Zargar,. Incidence of ethambutol-related visual impairment during treatment of active tuberculosis. Int J Tuberc Lung Dis. 2013;17:447–55
16. D.Falzon, E.Jaramillo, H.J.Schünemann,. WHO guidelines for the programmatic management of drug-resistant tuberculosis:2011 update. Eur Respir J. 2011;38:516–28
17. J.C.Johnston, N.C.Shahidi, M.Sadatsafavi,. Treatment outcomes of multidrug-resistant tuberculosis:a systematic review and meta-analysis. PLoS One. 2009;4:e6914. doi:10.1371/journal.pone.0006914
18. M.B.Conde, A.Efron, C.Loredo,. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis:a double-blind, randomised, controlled phase II trial. Lancet. 2009;373:1183–9
19. H.M.Ziglam, D.R.Baldwin, I.Daniels,. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600-mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 2002;50:1011–15
20. A.Soman, D.Honeybourne, J.Andrews,. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400-mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1999;44:835–8
21. A.D.Pranger, R.van Altena, R.E.Aarnoutse,. Evaluation of moxifloxacin for the treatment of tuberculosis:3 years of experience. Eur Respir J. 2011;38:888–94
22. R.Ruslami, A.R.Ganiem, S.Dian,. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis:an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13:27–35
23. Potter JL, Capstick T, Ricketts WM, et al. A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB. Thorax. Published Online First:13 June 2014. doi:10.1136/thoraxjnl-2014-205278
24. L.E.Ziganshina, A.F.Titarenko, G.R.Davies. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev. 2013;6:CD004795. doi:10.1002/14651858.CD004795.pub4
25. Pilheu JA, Maglio F, Cetrangolo R, et al. Concentrations of ethambutol in the cerebrospinal fluid after oral administration. Tubercle. 1971;52:117–22. Available from:http://www.ncbi.nlm.nih.gov/pubmed/5560732 [last accessed 18 Sep 2014]
26. J.W.C.Alffenaar, R.van Altena, H.J.Bökkerink,. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis. 2009;49:1080–2. doi:10.1086/605576
27. S.H.Gillespie, A.M.Crook, T.D.McHugh,. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014; 140907080012008. doi:10.1056/NEJMoa1407426
28. V.Gupta, R.Bansal, A.Gupta. Continuous progression of tubercular serpiginous-like choroiditis after initiating antituberculosis treatment. Am J Ophthalmol. 2011;152:857–63 e852